RECURSION PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Increase (Decrease) in Accounts Payable of -$5.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$7.67M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.07M, a 43.93% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $4.42M, a 45.59% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$5.89M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$2.62M, a 140.65% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2024 was $6.43M.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2023 was -$987.00K, a 155.86% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2022 was $1.77M, a 1.26% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.60M 10-Q · filed 2026-08-05 | -$1.18M derived: sum of 3 quarters · filed 2026-08-05 | -$7.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.07M 10-Q · filed 2026-05-06 | $6.49M derived: sum of 2 quarters · filed 2026-05-06 | $599.00K derived: sum of 3 quarters · filed 2026-05-06 | -$4.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.47M derived: sum of 2 quarters · filed 2026-02-25 | -$6.31M derived: sum of 3 quarters · filed 2026-08-05 | -$2.62M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$5.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$10.73M derived: sum of 2 quarters · filed 2026-08-05 | -$7.04M 10-Q · filed 2025-11-05 | $1.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$4.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.15M 10-Q · filed 2026-08-05 | $6.98M derived: sum of 3 quarters · filed 2026-08-05 | $5.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.69M 10-Q · filed 2026-05-06 | $11.81M derived: sum of 2 quarters · filed 2026-05-06 | $10.30M derived: sum of 3 quarters · filed 2026-05-06 | $8.96M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $8.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.61M derived: sum of 2 quarters · filed 2026-02-25 | $5.27M derived: sum of 3 quarters · filed 2026-02-25 | $6.43M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$2.85M derived: sum of 2 quarters · filed 2025-11-05 | -$1.69M 10-Q · filed 2025-11-05 | -$2.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$174.00K 10-Q · filed 2025-08-05 | -$491.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.70M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-05 | $851.00K derived: sum of 2 quarters · filed 2026-02-25 | $3.04M derived: sum of 3 quarters · filed 2026-02-25 | $520.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.87M derived: sum of 2 quarters · filed 2026-02-25 | -$648.00K derived: sum of 3 quarters · filed 2026-02-25 | -$987.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$331.00K derived: sum of 2 quarters · filed 2024-11-06 | -$670.00K 10-Q · filed 2024-11-06 | $25.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.86M 10-Q · filed 2024-08-08 | -$2.16M derived: sum of 3 quarters · filed 2025-02-28 | -$1.45M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$339.00K 10-Q · filed 2024-05-09 | $356.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.07M derived: sum of 3 quarters · filed 2025-02-28 | $84.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $695.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.41M derived: sum of 2 quarters · filed 2025-02-28 | $423.00K derived: sum of 3 quarters · filed 2025-02-28 | $1.77M 10-K · filed 2025-02-28 |
| 2022-09-30 | $714.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$272.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.07M 10-Q · filed 2023-11-09 | -$2.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$986.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $358.00K 10-Q · filed 2023-08-08 | -$3.15M derived: sum of 3 quarters · filed 2024-02-29 | -$19.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.34M 10-Q · filed 2023-05-08 | -$2.16M derived: sum of 2 quarters · filed 2024-02-29 | $967.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.04M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$377.00K derived: sum of 2 quarters · filed 2024-02-29 | -$306.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.75M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $3.20M derived: sum of 2 quarters · filed 2022-11-08 | $5.25M 10-Q · filed 2022-11-08 | $5.03M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.12M 10-Q · filed 2022-08-09 | $1.90M derived: sum of 3 quarters · filed 2023-02-27 | $1.84M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.05M 10-Q · filed 2022-05-10 | $1.83M derived: sum of 2 quarters · filed 2023-02-27 | $1.77M derived: sum of 3 quarters · filed 2023-02-27 | $1.24M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$277.00K derived: sum of 2 quarters · filed 2023-02-27 | -$810.00K derived: sum of 3 quarters · filed 2023-02-27 | -$185.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | -$55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$588.00K derived: sum of 2 quarters · filed 2021-11-10 | $37.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$533.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $92.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $625.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$340.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |